



A SLOW-MOTION EPIDEMIC

The symptoms of Crohn's disease and ulcerative colitis, the two main forms of inflammatory bowel disease (IBD), can be severe and lifelong. And the condition is becoming increasingly common worldwide. By **Michael Eisenstein**; illustration by **Lucy Reading-Ikkanda**


THE BATTLE WITHIN

In general, IBD is thought to occur when the immune system overreacts to the bacterial community that normally dwells in the gut, setting in motion a chain of inflammation events that can damage and destroy the intestinal wall.



SIMILAR, YET DIFFERENT

Most cases of IBD are classified as either ulcerative colitis (UC) or Crohn's disease (CD). The relative prevalence of these two conditions varies widely across different geographical regions (see chart). Between 5% and 15% of cases cannot immediately be put into either category and are instead referred to as 'indeterminate colitis'. Despite sharing similar symptoms, there are important pathological distinctions between the two main forms of IBD.




CROHN'S DISEASE

- Commonly occurs in the colon and lower small intestine, but can affect all of the gastrointestinal tract
- Can comprise multiple separate areas of inflammation
- Can damage all layers of the intestinal wall, forming deep perforations (see left)
- Symptoms include rectal bleeding, persistent diarrhoea, urgent need to move bowels, constipation, abdominal cramps and pain

ULCERATIVE COLITIS

- Generally affects only the sigmoid colon and rectum
- Forms a continuous patch of inflammation
- Damages the innermost lining of the intestinal wall (see left)
- Symptoms include bloody diarrhoea, abdominal cramps and pain




NATURE AND NURTURE

A variety of hereditary, environmental and lifestyle factors are thought to influence IBD pathology. However, researchers are still grappling with exactly how these elements individually and collectively affect the natural history of the disease.



Genetics

Up to 14% of people with IBD have a family history of the condition². The strongest genetic risk factor for CD is the gene *NOD2*, which regulates bacterial populations in the gut. The gene is mutated in 25–35% of Europeans with CD³.



Hygiene

In Western nations, lifestyle factors that expose young children to bacteria — such as living on a farm — may reduce IBD risk by enriching microbial diversity in the gut. Similarly, early antibiotic use, which disrupts these communities, is a risk factor.



Mental health

Stress, anxiety and depression are associated with both IBD risk and recurrence of the disease. Physical inactivity and disrupted sleep are also risk factors. Causality, however, is not yet well established.



Diet

Consumption of saturated fats and low intake of fruit and vegetable fibre may increase IBD risk. Vitamin D seems to help to control inflammation in people with IBD.




Smoking

Scientists investigating the effect of smoking on IBD risk have discovered an apparent contradiction: current smokers are nearly twice as likely to have CD as non-smokers, but they also seem to be at lower risk of UC.

A GROWING GLOBAL DISEASE

IBD is most common in North America, Western and Northern Europe, Australia and New Zealand⁴. Cases are much less common in non-Western nations, but this is changing — incidence rates have climbed rapidly in recent years in parts of Asia and South America.





IBD prevalence, 2015:

- Highest
- Intermediate
- Lowest
- No data



REGIONAL, LOCAL, INDIVIDUAL

Beneath the global data lie smaller-scale trends that reveal the complex mix of factors that determine a person's risk of disease.



Ashkenazi Jews living in Western nations are much more likely to have IBD than their non-Jewish neighbours⁹

Sources: 1. Molodecky, N. A. *et al. Gastroenterology* **142**, 46–54 (2012). 2. Ananthakrishnan, A. N. *Nature Rev. Gastroenterol. Hepatol.* **12**, 205–217 (2015). 3. Sartor, R. B. *et al. Nature Clin. Prac. Gastroenterol. Hepatol.* **3**, 390–407 (2006). 4. Kaplan, G. G. *Nature Rev. Gastroenterol. Hepatol.* **12**, 720–727 (2015). 5. Thia, K. T. *et al. Am. J. Gastroenterol.* **103**, 3167–3182 (2008). 6. Victoria, C. R. *et al. Arq. Gastroenterol.* **46**, 20–25 (2009). 7. Khalili, H. *Gut* **61**, 1686–1692 (2012). 8. Soon, I. S. *et al. BMC Gastroenterol.* **12**, 51 (2012). 9. Bernstein, C. N. *et al. Am. J. Gastroenterol.* **101**, 993–1002 (2006).